Stevanato (STVN) Q1 2026 Earnings Transcript

Stevanato Group posted Q1 revenue of EUR 273.6 million, up 10% at constant currency, driven by 16% growth in the BDS segment and 17% growth in high-value solutions to EUR 128.6 million. Adjusted EBITDA rose 14% to EUR 65.5 million, while management maintained full-year 2026 guidance for revenue of EUR 1.260 billion-EUR 1.290 billion and adjusted EPS of EUR 0.59-EUR 0.63. Offsetting the strength were a 31% decline in Engineering revenue, a 300 bps drop in BDS gross margin to 28.3%, and ongoing headwinds from depreciation, FX, tariffs, and inflation.

Analysis

The key read-through is not simply that demand is strong, but that capacity is now the binding constraint in the most attractive part of the mix. When bookings are already absorbing 2026 cartridge supply, incremental growth is effectively pre-sold, which reduces near-term revenue volatility but also shifts the debate to how quickly management can convert capex into billable output without blowing up working capital or margins.

The second-order effect is that the company is using its own engineering footprint as a capacity reallocation tool, which is a positive sign for capital efficiency and a subtle warning for peers. Converting underutilized lines into higher-value RTU formats implies the market is still underpenetrated, and that smaller packaging players without flexible assets may face a faster obsolescence curve once Annex 1 and GLP-driven demand move more volume into compliant sterile formats.

Near term, the main risk is that headline growth remains strong while gross margin optics stay noisy from depreciation, FX, and tariffs, creating a setup where consensus may overfocus on quarterly margin compression instead of throughput economics. The engineering recovery is more of a 6-12 month story than a 1-2 quarter story; the backlog gap means this segment can improve profitability before it meaningfully adds revenue, but if order conversion slips again, the market will start discounting the guidance bridge.

The contrarian angle is that the market may be underestimating the durability of GLP-related demand because it is framing the opportunity as a narrow obesity trade, when the real beneficiary is the broader injectable ecosystem. The more important variable is not whether orals grow, but whether the mix shifts toward larger-volume, higher-complexity delivery formats; if that happens, STVN’s cartridge and high-value syringe mix can keep expanding even with only mid-teens end-market growth.

Key Decisions for Investors

• Long STVN on a 3-6 month horizon into cartridge capacity conversion milestones; risk/reward favors upside if Q2/Q3 show revenue conversion from pre-booked demand. Use any post-earnings margin-driven selloff to add, since the capex is already deployed and revenue is likely to inflect before accounting noise clears.
• Pair trade: long STVN / short a lower-quality packaging or capital-equipment peer with less flexibility in sterile formats over 6-12 months. Thesis: flexible RTU capacity and Annex 1 exposure should re-rate relative to fixed-asset, slower-moving peers as demand rotates toward compliant high-value formats.
• Sell downside via STVN cash-secured puts or a bullish put spread expiring after the late-June cartridge production start. The catalyst is binary enough that implied volatility should overstate risk if the company executes on the line conversion and maintains 2026 guidance.
• Avoid shorting on the basis of near-term gross margin compression alone; if anything, use engineering weakness as a long-dated catalyst rather than a near-term trade. The revenue lag there is a timing problem, not clear evidence of share loss, so a short would be fighting both secular demand and operational leverage.
• Monitor for a tactical long-add if management reiterates second-half acceleration at the next update; if H2 starts to show revenue acceleration while depreciation stays stable, the multiple can expand before cash flow does.